Thromb Haemost 2004; 92(06): 1182-1193
DOI: 10.1160/TH04-05-0289
Theme Issue Article
Schattauer GmbH

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease

Richard C. Becker
1   Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA
2   Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
,
John Alexander
1   Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA
2   Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
,
Christopher K. Dyke
1   Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA
2   Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
,
Robert A. Harrington
1   Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina, USA
2   Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 10. Mai 2004

Accepted after revision 04. Oktober 2004

Publikationsdatum:
02. Dezember 2017 (online)

Zoom Image

Summary

The development of anticoagulants for treating patients with atherothrombotic disorders of the arterial circulatory system has focused, either directly or indirectly, on thrombin – a pleuripotential effector enzyme with prothrombotic and proinflammatory properties. The pivotal role of factor (f) Xa in thrombin generation, coupled with its direct cellular effects and widely recognized limitations of currently available anticoagulants, has led to the development of pharmacologic inhibitors of this important protease. The following review focuses on DX9065a – first in a class of direct, selective and reversible fXa antagonists – and its potential applications in the management of patients with cardiovascular disease.

Crossref Cited-by logo
Zitierungen